Nuveen LLC Purchases Shares of 156,882 Vera Therapeutics, Inc. $VERA

Key Points

• Nuveen LLC has acquired a new position in Vera Therapeutics, Inc. by purchasing 156,882 shares valued at approximately $3.77 million, representing a 0.25% ownership stake.
• Vera Therapeutics reported a quarterly EPS of ($1.20), missing analysts' expectations by $0.38, and is projected to have an earnings per share of -$2.89 for the current year.
• Recent analyst ratings for Vera Therapeutics show a consensus of "Moderate Buy" with an average price target of $63.00, reflecting mixed opinions on the stock's future performance.

Nuveen LLC acquired a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 156,882 shares of the company's stock, valued at approximately $3,768,000. Nuveen LLC owned approximately 0.25% of Vera Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new stake in Vera Therapeutics in the 4th quarter valued at about $56,000. Invesco Ltd. increased its position in Vera Therapeutics by 7.0% in the 4th quarter. Invesco Ltd. now owns 21,954 shares of the company's stock valued at $928,000 after acquiring an additional 1,444 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Vera Therapeutics by 19.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,533 shares of the company's stock valued at $229,000 after acquiring an additional 1,572 shares in the last quarter. Bank of New York Mellon Corp increased its position in Vera Therapeutics by 1.2% in the 1st quarter. Bank of New York Mellon Corp now owns 143,665 shares of the company's stock valued at $3,451,000 after acquiring an additional 1,717 shares in the last quarter. Finally, Ensign Peak Advisors Inc increased its position in Vera Therapeutics by 15.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 13,550 shares of the company's stock valued at $573,000 after acquiring an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

Insiders Place Their Bets

In other news, Director Patrick G. Enright acquired 209,393 shares of Vera Therapeutics stock in a transaction that occurred on Monday, June 23rd. The shares were acquired at an average price of $20.87 per share, with a total value of $4,370,031.91. Following the purchase, the director directly owned 3,569,522 shares of the company's stock, valued at $74,495,924.14. The trade was a 6.23% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 16.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on VERA shares. JPMorgan Chase & Co. reduced their target price on shares of Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $85.00 target price (up previously from $75.00) on shares of Vera Therapeutics in a research note on Monday, June 2nd. Wolfe Research reaffirmed a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Scotiabank reaffirmed an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Finally, Guggenheim reaffirmed a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Vera Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $63.00.

Vera Therapeutics Trading Down 2.9%

Vera Therapeutics stock traded down $0.65 during midday trading on Monday, hitting $21.64. 2,121,800 shares of the stock were exchanged, compared to its average volume of 1,796,484. The company has a fifty day simple moving average of $22.19 and a two-hundred day simple moving average of $23.52. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $51.61. The stock has a market capitalization of $1.38 billion, a PE ratio of -6.04 and a beta of 1.17. The company has a quick ratio of 17.03, a current ratio of 17.03 and a debt-to-equity ratio of 0.16.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same period last year, the company earned ($0.62) EPS. Equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.